Our present examinations together with our previous results [4] indicated that at least certain structural variants of DS can significantly stimulate the activation of the necroptotic effector MLKL in various luminal breast cancer cell lines, including both the primary tumor and metastatic cells. The gene discussed is MLKL; the disease is breast cancer.